title: Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain.
abstract: OBJECTIVE
  In dental applications, as in all other medical applications, pain needs to be prevented or at least controlled. The use of the tooth as a model for studying pain mechanisms is well established. In the current study, we aimed to evaluate and compare the analgesic effects of gabapentin and lornoxicam, respectively, vs a placebo for postendodontic treatment pain.
  
  
  METHODS
  Clinical research was planned as prospective, randomized, and placebo controlled. Each subject was given 600 mg gabapentin (group G: N = 30), 8 mg lornoxicam (group L: N = 30), or a placebo (group C: N = 30) 30 min prior to endodontic treatment.
  
  
  METHODS
  At 4 (T(3)), 8 (T(4)), 12 (T(5)), and 24 (T(6)) h after preoperative (T(0)) time points, the analgesic efficacies of the agents were evaluated by using the visual analog scale (VAS).
  
  
  RESULTS
  In group G, VAS values were significantly greater at T(0) time point than at T(5) or T(6). T(0) time point VAS value in group L was lower than at T4 time point and greater than at T(6). In group C, T(0) time point VAS values were significantly lower at T(3) and T(5) time points and greater than at T(6) time point. VAS values in group G at T(5) time point were significantly lower than in group C or group L (P < 0.05).
  
  
  CONCLUSIONS
  Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo.
authors.affiliation: Department of Anesthesiology and Reanimation, Faculty of Medicine, Gazi University, Ankara, Turkey.
authors.forename: Berrin
authors.initials: B
authors.lastname: Işik
authors.forename: Sis
authors.initials: S
authors.lastname: Yaman
authors.forename: Serkan
authors.initials: S
authors.lastname: Aktuna
authors.forename: Alparslan
authors.initials: A
authors.lastname: Turan
mesh_terms: D000328:Adult; D000588:Amines / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D059408:Pain Management / Q000379:methods; D010147:Pain Measurement; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D012390:Root Canal Therapy / Q000009:adverse effects*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D010894:Piroxicam; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; C059451:lornoxicam
keywords: Analgesia; Gabapentin; Lornoxicam; Prophylactic